Over the last decade requests for the measurement of 25-hydroxy vitamin D (25-OHD) have risen exponentially. For example, statistics from the Australian government provides evidence for a 100-fold increase between 2000 and 2010 (1) . This burst of vitamin D requests has several causes including an increased awareness of the medical community and the general population to the high prevalence of vitamin D defi ciency and its relevance for osteoporosis, cardiovascular disease, malignancies, infectious and autoimmune disease. The massively increased demand for 25-OHD testing has important implications for healthcare systems and clinical laboratories. Whereas healthcare systems worldwide face an explosion of costs for 25-OHD testing, laboratories have to adopt methods that can cope with the elevated workload. External quality control programs show that most laboratories use automated immunoassays. Diagnostic manufacturers have identifi ed 25-OHD as a highly profi table and strategic test, which has lead to the commercialization of new automated immunoassays during recent years. However, it has to be acknowledged that 25-OHD is a challenging analyte to accurately measure in human blood (2) . Analytical diffi culties are related to its lipohilic nature, strong affi nity to vitamin D binding protein (VDBP) and association with human serum albumin, as well as the presence of very low to high levels of 25-OH vitamin D 3 (25-OHD 3 ) and/or 25-OH vitamin D 2 (25-OHD 2 ), multiple 25-OHD metabolites (e.g., 24,25-dihydroxy vitamin D 3 ), C3-epimer of 25-OHD 3 and 25-OHD 2 (25-OHD 3 -epi and 25-OHD 2 -epi), and other sources of assay interference, such as heterophilic antibodies. Therefore, 25-OH vitamin D immunoassays are required to detect 25-OHD 2 and 25-OHD 3 in an equimolar fashion and report a total 25-OHD result.
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Previous automated immunoassay comparison studies have demonstrated signifi cant analytical limitations for some of these assays (2, 3) . External quality assurance programs, such as DEQAS, or the Quality Assurance Program of the Royal Australian College of Pathologists, also show a wide spread of reported results for the same sample, which in some cases vary from defi cient ( < 25 nmol/L) to suffi cient ( > 75 nmol/L). Analytical problems of 25-OHD immunoassays have also been noted by clinicians who often question the laboratory about results that do not correspond to the clinical picture of their patients. The apparent issues of automated immunoassays have resulted in the worldwide withdrawal of the Roche 25-OHD 3 assay in 2010 and to the modifi cation of the assay conditions of several other commercial immunoassays, such as SIEMENS Centaur, Abbott ARCHITECT and DiaSorin LIAISON. Regulatory bodies, such as the FDA have also become aware of analytical issues with some of the recently launched assays. For example, the FDA has imposed certain conditions on some of the recently cleared 510(k) assays, such as limiting the measuring range of the Abbott ARCHITECT assay from 13 ng/mL (32.5 nmol/ < L) to 96 ng/mL (240 nmol/L).
The fi rst automated vitamin D immunoassay was a vitamin D binding protein (VDBP) based test developed for the Nichols Advantage analyzer (4) . This assay underestimated 25-OHD at low levels and overestimated 25-OHD at high levels resulting in a substantial misclassifi cation of patients (5) . A comparison of the Nichols Advantage assay with liquid chromatography tandem mass spectrometry (LC-MS/MS) also revealed problems with assay linearity (6) and individual patient results were highly variable. Due to these and other issues the Nichols binding protein assay was discontinued and companies like DiaSorin and Roche developed assays that employ specifi c antibodies to capture 25-OHD. While the DiaSorin LIAISON test used a polyclonal antibody with 100 % and 104 % cross-reactivity to 25-OHD 3 and 25-OHD 2 , respectively, the Roche assay employed an antibody that cross-reacted 100 % with 25-OHD 3 with no cross-reactivity to 25-OHD 2 . Methods like the Abbott ARCHITECT, DiaSorin LIAISON, IDS iSYS and Siemens Centaur have a competitive format where analyte concentration and signal intensity are inversely related, but they have different mechanisms for signal generation (e.g., vitamin D analogue and conjugate capture approach). Recently, Roche Diagnostics launched a new total vitamin D assay, which uses recombinant VDBP instead of an antibody to capture 25-OHD. Unlike the previous 25-OHD 3 specifi c assay this approach allows the detection of both 25-OHD 3 and 25-OHD 2 . Importantly, the test is standardized against LC-MS/MS with traceability to the NIST 972 standard reference material. In this issue of Clinical Chemistry and Laboratory Medicine several comparison and evaluation studies assessed the performance of the new Roche total and other latest generation automated 25-OHD immunoassays (7 -12) . Virtually all of these studies concluded that the performance of most assays was acceptable and that they were suitable for routine use. Although the analytical performance of most 25-OHD immunoassays has improved, signifi cant issues remain. For example, it is questionable if a correlation of r = 0.90 between two methods which are supposedly measuring the same analyte can be regarded as ' adequate for the purpose ' , and the studies by Emmen et al. (7) or Franken et al. (12) highlight this. Furthermore, a narrow linear range of 7.5 -175 nmol/L, such as the one of the Roche assay, requires dilution to identify samples with toxic 25-OHD levels ( > 250 nmol/L) making the diagnosis of intoxication cumbersome.
The 25-OHD assay comparison studies in this issue of CCLM unequivocally demonstrate that most automated immunoassays are able to detect 25-OHD 3 with reasonable precision and accuracy (7 -12) . Only the SIEMENS Centaur assay appears to not achieve satisfactory performance (2, 11) . If read uncritically one may conclude that latest generation assays are fi t for purpose. However, the design of most of these studies does not address the following analytical and clinical aspects that impact assay performance under routine conditions, and do not truly establish if a given immunoassay is clinically fi t for use:
Most of the studies published do not adequately challenge 1) claimed immunoassay measuring ranges and linearity. -epimer, a metabolite with reported reduced biological activity, also affects assay performance (15) . The study by Farrell et al. demonstrated the presence of 25-OHD 3 -epimer in about 40 % of the study population. 25-OHD 3 -epi levels ranged between 5 and 14 nmol/L. While most of the automated immunoassays claim that they do not cross-react with 25-OHD 3 -epi the new Roche assay does capture this metabolite. Therefore, to properly interpret the performance of an immunoassay it is important to know if this assay and the reference method used for comparison detect 25-OHD 3 -epi (11) .
Another major problem is that the LC-MS/MS reference 4) methods that were used were not harmonized. They were all different and were unaligned to any of the recently endorsed standard reference methods (15, 16) . Although the introduction of the NIST 972 reference material has improved the comparability of LC-MS/MS methods, profi ciency testing programs around the world shows that there is still substantial variation between these methods. Heterophilic antibodies may affect immunoassay perfor-5) mance and are typically found at rates of < 1 in 1000. In a routine setting where a given test is used to measure tens of thousands of samples such interference can cause substantial problems. Therefore, in addition to the samples selected to span the assay measuring range, method comparison studies should also challenge the test methods with a set of samples known to contain heterophilic antibodies.
As it is very diffi cult to identify and source samples with interfering heterophilic antibodies, it is more practical to question assay results that do not fi t the clinical picture and refl ex test these samples by a heterophilic antibodyfree reference method, such as LC-MS/MS. For example, samples with doses outside the normal/reference range of a given assay are likely candidates for heterophilic interference if the LC-MS/MS results are signifi cantly different from the test method.
How these aspects affect assay performance is nicely shown in the study Farrell et al. where automated 25-OHD immunoassays were specifi cally challenged with high and low samples as well as samples containing 25-OHD 2 and heterophilic antibodies (11) .
In conclusion, assay comparison studies should specifi cally challenge the assays to report a true and robust total 25-OHD value across the claimed measuring range of a given assay. This includes the measurement of serum samples containing endogenous 25-OHD 2 , 25-OHD 3 -and 25-OHD epi, as well as selected samples with interfering heterophilic antibodies. Furthermore, LC-MS/MS methods that are used for comparison should be aligned to one of the recently endorsed standard reference methods (15, 16) . And last but not least, there is a need to adopt robust criteria for the decision if the performance of an assay is acceptable for routine use.
